Literature DB >> 18479957

Upregulation of elastase proteins results in aortic dilatation in mucopolysaccharidosis I mice.

Xiucui Ma1, Mindy Tittiger, Russell H Knutsen, Attila Kovacs, Laura Schaller, Robert P Mecham, Katherine P Ponder.   

Abstract

Mucopolysaccharidosis I (MPS I), known as Hurler syndrome in the severe form, is a lysosomal storage disease due to alpha-L-iduronidase (IDUA) deficiency. It results in fragmentation of elastin fibers in the aorta and heart valves via mechanisms that are unclear, but may result from the accumulation of the glycosaminoglycans heparan and dermatan sulfate. Elastin fragmentation causes aortic dilatation and valvular insufficiency, which can result in cardiovascular disease. The pathophysiology of aortic disease was evaluated in MPS I mice. MPS I mice have normal elastic fiber structure and aortic compliance at early ages, which suggests that elastin assembly is normal. Elastin fragmentation and aortic dilatation are severe at 6 months, which is temporally associated with marked increases in mRNA and enzyme activity for two elastin-degrading proteins, matrix metalloproteinase-12 (MMP-12) and cathepsin S. Upregulation of these genes likely involves activation of STAT proteins, which may be induced by structural stress to smooth muscle cells from accumulation of glycosaminoglycans in lysosomes. Neonatal intravenous injection of a retroviral vector normalized MMP-12 and cathepsin S mRNA levels and prevented aortic disease. We conclude that aortic dilatation in MPS I mice is likely due to degradation of elastin by MMP-12 and/or cathepsin S. This aspect of disease might be ameliorated by inhibition of the signal transduction pathways that upregulate expression of elastase proteins, or by inhibition of elastase activity. This could result in a treatment for patients with MPS I, and might reduce aortic aneurism formation in other disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18479957      PMCID: PMC3775334          DOI: 10.1016/j.ymgme.2008.03.018

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  46 in total

1.  Function and regulation of osteopontin in response to mechanical stress.

Authors:  Shinji Fujihara; Masahiko Yokozeki; Yasuo Oba; Yuji Higashibata; Shintaro Nomura; Keiji Moriyama
Journal:  J Bone Miner Res       Date:  2006-06       Impact factor: 6.741

2.  PU.1 regulates cathepsin S expression in professional APCs.

Authors:  Ying Wang; Rebecca M Baron; Guangli Zhu; Myungsoo Joo; John W Christman; Eric S Silverman; Mark A Perrella; Richard J Riese; Manuela Cernadas
Journal:  J Immunol       Date:  2006-01-01       Impact factor: 5.422

Review 3.  Advances in cathepsin S inhibitor design.

Authors:  John O Link; Sheila Zipfel
Journal:  Curr Opin Drug Discov Devel       Date:  2006-07

Review 4.  IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors.

Authors:  Kenya Honda; Tadatsugu Taniguchi
Journal:  Nat Rev Immunol       Date:  2006-09       Impact factor: 53.106

5.  Cardiac functional and histopathologic findings in humans and mice with mucopolysaccharidosis type I: implications for assessment of therapeutic interventions in hurler syndrome.

Authors:  Elizabeth Braunlin; Shannon Mackey-Bojack; Angela Panoskaltsis-Mortari; James M Berry; Ron T McElmurry; Megan Riddle; Li-Yan Sun; Lorne A Clarke; Jakub Tolar; Bruce R Blazar
Journal:  Pediatr Res       Date:  2005-12-02       Impact factor: 3.756

6.  Signal transducers and activators of transcription-3 up-regulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer.

Authors:  Jennifer Dien; Hesham M Amin; Neil Chiu; Winson Wong; Christine Frantz; Brian Chiu; John R Mackey; Raymond Lai
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

7.  Expression of matrix metalloproteinases, their tissue inhibitors, and osteopontin in the wall of thoracic and abdominal aortas with dilatative pathology.

Authors:  Vaiva Lesauskaite; Maria Carmela Epistolato; Marta Castagnini; Sigitas Urbonavicius; Piero Tanganelli
Journal:  Hum Pathol       Date:  2006-06-19       Impact factor: 3.466

8.  Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I.

Authors:  Elizabeth A Braunlin; James M Berry; Chester B Whitley
Journal:  Am J Cardiol       Date:  2006-06-12       Impact factor: 2.778

9.  Development of selective inhibitors and substrate of matrix metalloproteinase-12.

Authors:  Laurent Devel; Vassilis Rogakos; Arnaud David; Anastasios Makaritis; Fabrice Beau; Philippe Cuniasse; Athanasios Yiotakis; Vincent Dive
Journal:  J Biol Chem       Date:  2006-02-15       Impact factor: 5.157

Review 10.  The Ets transcription factors of the PEA3 group: transcriptional regulators in metastasis.

Authors:  Yvan de Launoit; Jean-Luc Baert; Anne Chotteau-Lelievre; Didier Monte; Laurent Coutte; Sébastien Mauen; Virginie Firlej; Cindy Degerny; Kathye Verreman
Journal:  Biochim Biophys Acta       Date:  2006-03-03
View more
  29 in total

1.  Pathogenesis of aortic dilatation in mucopolysaccharidosis VII mice may involve complement activation.

Authors:  Guilherme Baldo; Susan Wu; Ruth A Howe; Meera Ramamoothy; Russell H Knutsen; Jiali Fang; Robert P Mecham; Yuli Liu; Xiaobo Wu; John P Atkinson; Katherine P Ponder
Journal:  Mol Genet Metab       Date:  2011-08-24       Impact factor: 4.797

2.  Sub-pleural bullous changes in two adults with Mucopolysaccharidosis type I (Hurler-Scheie).

Authors:  Michel C Tchan; Nicole Graf; David O Sillence
Journal:  J Inherit Metab Dis       Date:  2011-02-01       Impact factor: 4.982

3.  Mechanism of shortened bones in mucopolysaccharidosis VII.

Authors:  Jason A Metcalf; Yanming Zhang; Matthew J Hilton; Fanxin Long; Katherine P Ponder
Journal:  Mol Genet Metab       Date:  2009-03-25       Impact factor: 4.797

4.  The transforming growth factor-Beta signaling pathway involvement in cardiovascular lesions in mucopolysaccharidosis-I.

Authors:  S Yano; C Li; Z Pavlova
Journal:  JIMD Rep       Date:  2012-04-18

5.  Differential expression of matrix metalloproteinases in the serum of patients with mucopolysaccharidoses.

Authors:  Spyros P Batzios; Dimitrios I Zafeiriou; Euthymia Vargiami; George Karakiulakis; Eleni Papakonstantinou
Journal:  JIMD Rep       Date:  2011-09-22

6.  Network Analysis Reveals Proteins Associated with Aortic Dilatation in Mucopolysaccharidoses.

Authors:  Thiago Corrêa; Bruno César Feltes; Esteban Alberto Gonzalez; Guilherme Baldo; Ursula Matte
Journal:  Interdiscip Sci       Date:  2021-01-21       Impact factor: 2.233

7.  Gene therapy for cardiovascular manifestations of lysosomal storage diseases.

Authors:  Meg M Sleeper; Mark E Haskins; Katherine P Ponder
Journal:  Heart Metab       Date:  2008

8.  Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology.

Authors:  Mark J Osborn; Beau R Webber; Ronald T McElmurry; Kyle D Rudser; Anthony P DeFeo; Michael Muradian; Anna Petryk; Benedikt Hallgrimsson; Bruce R Blazar; Jakub Tolar; Elizabeth A Braunlin
Journal:  J Inherit Metab Dis       Date:  2016-10-14       Impact factor: 4.982

9.  Mechanical testing of mouse carotid arteries: from newborn to adult.

Authors:  Mazyar Amin; Victoria P Le; Jessica E Wagenseil
Journal:  J Vis Exp       Date:  2012-02-23       Impact factor: 1.355

10.  Gender-related dimorphism in aortic insufficiency in murine mucopolysaccharidosis type I.

Authors:  Jakub Tolar; Elizabeth Braunlin; Megan Riddle; Brandon Peacock; Ron T McElmurry; Paul J Orchard; Bruce R Blazar
Journal:  J Heart Valve Dis       Date:  2009-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.